Indeed, a number of recently developed small molecule modulators selectively targeting S1PR2 or S1PR3 [2, 17, 18], some with extensive clinical testing [2, 85], appear well positioned to be deployed to regulate CSC function in the therapy of both hematologic malignancies and solid tumours. Here, S1PR2 is linked to hematologic disorder.